Find Reports

Select Report Type

Reimbursement Review

Displaying 351 - 375 of 1426

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
semaglutide	Rybelsus	semaglutide	Recommendation and Reasons: Updated Recommendation and Reasons - Original Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	diabetes mellitus, type 2	Reimburse with clinical criteria and/or conditions	Complete	Nov 26, 2020	Jun 8, 2021	SR0637-000
luspatercept	Reblozyl	luspatercept	CADTH_reimbursement_recommendation_luspatercept_(reblozyl).pdf Reblozyl - Patient Group Input for Posting.pdf Stakeholder feedback on Draft Recommendation Clinical and Pharmacoeconomic combined Report	beta-thalassemia associated anemia	Reimburse with clinical criteria and/or conditions	Complete	Nov 26, 2020	Jun 8, 2021	SR0669-000
dupilumab	Dupixent	dupilumab	CADTH_reimbursement_recommendation_dupilumab_(dupixent).pdf SR0667 Dupixent - Patient Input Submission_For Posting.pdf Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation Clinician Input	Asthma	Reimburse with clinical criteria and/or conditions	Complete	Nov 26, 2020	Jun 8, 2021	SR0667-000
patiromer	Veltassa	patiromer	CADTH_reimbursement_recommendation_patiromer_(veltassa).pdf SR0665 Veltassa - Patient Input Submission.pdf Clinical and Pharmacoeconomic combined Report Clinician Input Stakeholder Feedback on Draft Recommendation	Hyperkalemia, adults (chronic kidney disease)	Reimburse with clinical criteria and/or conditions	Complete	Oct 30, 2020	Jun 8, 2021	SR0665-000
Dabrafenib and Trametinib for ...	Tafinlar and Mekinist	Dabrafenib and Trametinib	10226Dabrafenib-TrametinibNSCLC_inRec_pERC Chair Approved_Post01Apr2021_final.pdf Dabrafenib-Trametinib NSCLC BRAF V600 – pERC Final Recommandation Dabrafenib-Trametinib NSCLC BRAF V600 – Final Economic Guidance Report Dabrafenib-Trametinib NSCLC BRAF V600 – Final Clinical Guidance Report Dabrafenib-Trametinib NSCLC BRAF V600 – PAG Feedback on Initial Recommendation Dabrafenib-Trametinib NSCLC BRAF V600 – Manufacturer Feedback on Initial Recomm…Dabrafenib-Trametinib NSCLC BRAF V600 – Patient Advocacy Group Feedback on Init…Dabrafenib-Trametinib NSCLC BRAF V600 – Clinician Feedback on Initial Recommend…Dabrafenib-Trametinib NSCLC BRAF V600 – Patient Advocacy Group COI Declarations Dabrafenib-Trametinib NSCLC BRAF V600 – Clinician COI Declarations	NSCLC BRAF V600	Reimburse with clinical criteria and/or conditions	Complete	Oct 1, 2020	May 28, 2021	PC0226-000
ranolazine	Corzyna	ranolazine	sr0655CL-corzyna.pdf sr0655PE-corzyna.pdf Reasons and Recommendations	Stable angina pectoris, adults	Do not reimburse	Complete	Aug 17, 2020	May 27, 2021	SR0655-000
Chronic Lymphocytic Leukemia			Final Report	B-Cell Precursor Acute Lymphoblastic Leukemia		Completed		May 18, 2021	PH0004-000
Sonidegib (Odomzo) for Basal C...	Odomzo	Sonidegib	10215SonidegibBCC_fnRec_Post29Apr2021_final.pdf 10215SonidegibBCC_fnEGR_NOREDACT-ABBREV_Post29Apr2021_final.pdf 10215SonidegibBCC_fnCGR_NOREDACT_Post29Apr2021_final.pdf 10215SonidegibBCC_inRec_Post04Mar2021_final.pdf 10215SonidegibBCC_PAGFeedbackSummary_Post29Apr2021_final.pdf 10215SonidegibBCC_SponsorFeedback_Post29Apr2021_final_Redacted.pdf 10215SonidegibBCC_PatientFeedback_Combined_Post29Apr2021_final_Redacted.pdf 10215SonidegibBCC_ClinicianFeedback_CCO_Post29Apr2021_final_Redacted.pdf 10215SonidegibBCC_PatientCOI_Combined_Post29Apr2021_final_Redacted.pdf 10215SonidegibBCC_ClinicianInput_Combined_COIs Post29Apr2021_final_Redacted.pdf	Basal Cell Carcinoma	Do not reimburse	Complete	Jun 19, 2020	Apr 29, 2021	PC0215-000
Niraparib (Zejula) for first l...	Zejula	Niraparib	10224NiraparibOC_fnRec_pERC Chair Approved_Post29Apr2021_final.pdf 10224NiraparibOC_fnEGR_REDACT-ABBREV_Post29Apr2021_final.pdf 10224NiraparibOC_fnCGR_NOREDACT_Post29Apr2021_final.pdf 10224NiraparibOC_inRec_pERC Chair Approved_Post04Mar2021_final.pdf 10224NiraparibOC_PAGFeedbackSummary_Post29Apr2021_final_Redacted.pdf 10224NiraparibOC_SponsorFeedback_Post29Apr2021_final.pdf 10224NiraparibOC_PatientFeedback_OCC_Post29Apr2021_final.pdf 10224NiraparibOC_ClinicianFeedback_CCO_Post29Apr2021_final.pdf 10224NiraparibOC_Patient COI_OCC_Post29Apr2021_final.pdf 10224NiraparibOC_Combined Clinician COIs_Post29Apr2021_final.pdf	First Line OC	Reimburse with clinical criteria and/or conditions	Complete	Sep 21, 2020	Apr 29, 2021	PC0224-000
infliximab	Remsima	infliximab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions	Rheumatoid arthritis	Reimburse with clinical criteria and/or conditions	Complete	Sep 24, 2020	Apr 22, 2021	SR0659-000
Polatuzumab Vedotin (Polivy) f...	Polivy	Polatuzumab Vedotin	10227PolatuzumabDLBCL_fnRec_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_fnEGR_REDACT-ABBREV_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_fnCGR_NOREDACT_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_inRec_pERC Chair Approved_Post01Apr2021_final.pdf 10227PolatuzumabDLBCL_PAG Feedback_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_SponsorFeedback_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_PatientFeedback_LC_Final_Redacted.pdf 10227PolatuzumabDLBCL_ClinicianFeedback_CCO_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_Patient COI_LC_EC21Apr2021_final.pdf 10227PolatuzumabDLBCL_Combined Clinician COIs EC21Apr2021_final_Redacted.pdf	Diffuse large B-cell lymphoma (DLBCL)	Reimburse with clinical criteria and/or conditions	Complete	Sep 29, 2020	Apr 21, 2021	PC0227-000
Brigatinib (Alunbrig) for Anap...	Alunbrig	Brigatinib	10230BrigatinibALK+NSCLC_fnRec_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_fnEGR_REDACT-ABBREV_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_fnCGR_NOREDACT_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_inRec_approvedbyChair_Post01Apr2021_final.pdf 10230BrigatinibALK+NSCLC_PAGFeedback_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_SponsorFeedback_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_PatientFeedback_LCC_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_Combined ClinicianFeedback_EC21Apr2021.pdf 10230BrigatinibALK+NSCLC_Patient COI_EC21Apr2021_final.pdf 10230BrigatinibALK+NSCLC_Combined_COIs EC21Apr2021_final.pdf	(ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)	Reimburse with clinical criteria and/or conditions	Complete	Sep 30, 2020	Apr 21, 2021	PC0230-000
Olaparib (Lynparza) for metast...	Lynparza	Olaparib	10223OlaparibmCRPC_fnRec_REDACT_EC21Apr2021_final.pdf 10223OlaparibmCRPC_fnEGR_NOREDACT-ABBREV_EC21Apr2021_final.pdf 10223OlaparibmCRPC_fnCGR_REDACT_EC21Apr2021_final.pdf 10223OlaparibmCRPC_inRec_approvedbyChair_REDACT_Post01Apr2021_final.pdf 10223OlaparibmCRPC_PAGFeedback_EC21Apr2021_final_Redacted.pdf 10223OlaparibmCRPC_SponsorFeedback_EC21Apr2021_final.pdf 10223OlaparibmCRPC_ClinicianFeedback_EC21Apr2021_final.pdf 10223OlaparibmCRPC_Patient COI_CCSN_EC21Apr2021_final.pdf 10223OlaparibmCRPC_Combined Clinician COI_EC21Apr2021_final_Redacted.pdf	metastatic castration-resistant prostate cancer (mCRPC)	Reimburse with clinical criteria and/or conditions	Complete	Sep 22, 2020	Apr 21, 2021	PC0223-000
Unresectable Hepatocellular Ca...			Final Report	Unresectable Hepatocellular Carcinoma		Complete		Apr 21, 2021	PH0003-000
satralizumab	Enspryng	satralizumab	SR0663 Enspryng - CDEC Final Recommendation April 23, 2021_for posting.pdf SR0663 Enspryng - Patient Input Group - For posting.pdf Clinical Review Report	Neuromyelitis optica spectrum disorder	Reimburse with clinical criteria and/or conditions	Complete	Oct 22, 2020	Apr 21, 2021	SR0663-000
amifampridine	Ruzurgi	amifampridine	SR0660 Ruzurgi - CDEC Final Recommendation April 23, 2021_For posting.pdf sr0660-ruzurgi-clinical-review-report.pdf sr0660-ruzurgi-pharmacoeconomic-review-report.pdf	Lambert-Eaton myasthenic syndrome	Reimburse with clinical criteria and/or conditions	Complete	Oct 5, 2020	Apr 20, 2021	SR0660-000
Isatuximab (Sarclisa) for Mult...	Sarclisa	Isatuximab	10220IsatuximabMM_fnRec_pERC Chair Approved_Post01Apr2021_final.pdf 10220IsatuximabMM_fnEGR_NOREDACT-ABBREV_Post01Apr2021_final.pdf 10220IsatuximabMM_fnCGR_NOREDACT_Post01Apr2021_final.pdf 10220IsatuximabMM_inRec_pERC Chair Approved_Post4Feb2021_final.pdf 10220IsatuximabMM_PAGFeedbackSummary_Post01Apr2021_final_Redacted.pdf 10220IsatuximabMM_SponsorFeedback_Post01Apr2021_final_Redacted.pdf 10220IsatuximabMM_PatientFeedback_MC_Post01Apr2021_final_Redacted.pdf 10220IsatuximabMM_ClinicianFeedback_CCO_Post01Apr2021_final_Redacted.pdf 10220IsatuximabMM_Patient_COI_MyelomaCanada_Post01Apr2021_final.pdf 10220IsatuximabMM_Clinician_Combined_COIs_Post_final_Redacted.pdf	Multiple Myeloma	Reimburse with clinical criteria and/or conditions	Complete	Aug 17, 2020	Apr 1, 2021	PC0220-000
sacubitril/valsartan	Entresto	sacubitril/valsartan	SR0644 Entresto - CDEC Final Recommendation March 26, 2021 (Redacted)_for Posting.pdf SR0644_Entresto Resubmission_PI Submission.pdf	Heart failure, NYHA Class II or III	Reimburse with clinical criteria and/or conditions	Complete	May 22, 2020	Mar 24, 2021	SR0644-000
fremanezumab	Ajovy	fremanezumab	Recommendation and Reasons Clinical Report Pharmacoeconomic Report Patient Group Input Submission	migraine	Reimburse with clinical criteria and/or conditions	Complete	Jun 3, 2020	Mar 24, 2021	SR0641-000
onasemnogene abeparvovec	Zolgensma	onasemnogene abeparvovec	Recommendation and Reasons Clinical Report Pharmacoeconomic Report Patient Group Input Submission Implementation Advice	Spinal muscular atrophy (SMA), pediatrics	Reimburse with clinical criteria and/or conditions	Complete	Jun 25, 2020	Mar 24, 2021	SG0649-000
Avelumab (Bavencio) for Urothe...	Bavencio	Avelumab	10225AvelumabUC_FnRec_REDACT_EC23Mar2021_final.pdf 10225AvelumabUC_fnEGR_REDACT-ABBREV_EC23Mar2021_final.pdf 10225AvelumabUC_fnCGR_REDACT_EC23Mar2021_final.pdf 10225AvelumabUC_inRec_redacted_Post04Mar2021_final.pdf 10225AvelumabUC_PAGFeedbackSummary_EC23Mar2021_final.pdf 10225AvelumabUC_SponsorFeedback_EC23Mar2021_final.pdf 10225AvelumabUC_PatientFeedback_BCC_EC23Mar2021_final_Redacted.pdf 10225AvelumabUC_CinicianFeedback_CCO_EC23Mar2021_final.pdf 10225AvelumabUC_COI_BCC__Redacted.pdf 10225AvelumabUC_COI_CCO_EC23Mar2021_final.pdf	Urothelial Carcinoma (UC)	Reimburse with clinical criteria and/or conditions	Complete	Sep 18, 2020	Mar 23, 2021	PC0225-000
von Willebrand Factor [recombi...	Vonvendi	von Willebrand Factor [recombinant]	ST0639 Vonvendi - Final CPEC Recommendation March 22, 2021 for posting.pdf ST0639_Vonvendi_PI Submission.pdf Clinical Report Pharmacoeconomic Report	von Willebrand disease, adults, treatment and perioperative management	Reimburse with clinical criteria and/or conditions	Complete	Apr 29, 2020	Mar 17, 2021	ST0639-000
Nivolumab-Ipilimumab for Non-S...	Opdivo in combination with Yervoy	Nivolumab in combination with Ipilimumab	10218Nivolumab-IpilimumabNSCLC_FnRec_pERC Chair Approved_redact Post04Mar2021_final.pdf 10218Nivolumab-IpilimumabNSCLC_fnEGR_NOREDACT-ABBREV_Post04Mar2021_final.pdf 10218Nivolumab-IpilimumabNSCLC_fnCGR_REDACT_Post04Mar2021_final.pdf 10218Nivolumab-IpilimumabNSCLC_InRec_pERC Chair Approved_REDACT_Post08Jan2021_final.pdf 10218Nivolumab-IpilimumabNSCLC_PAG Feedback_Post04Mar2021_final_Redacted.pdf 10218Nivolumab-IpilimumabNSCLC_SponsorFeedback_Post04Mar2021_final_Redacted.pdf 10218Nivolumab-IpilimumabNSCLC_PatientFeedback_LCC__Post04Mar2021_final_Redacted.pdf 10218Nivolumab-IpilimumabNSCLC_Combined_ClinicianFeedback_Post04Mar2021_final-Redacted.pdf 10218Nivolumab-IpilimumabNSCLC_Patient Combined COI_Post04Mar2021_final_Redacted.pdf 10218Nivolumab-IpilimumabNSCLC_Combined_COIs_Post04Mar2021_final_Redacted.pdf	NSCLC	Reimburse with clinical criteria and/or conditions	Complete	Jun 23, 2020	Mar 4, 2021	PC0218-000
ofatumumab	Kesimpta	ofatumumab	SR0657 Kesimpta - CDEC Final Recommendation March 1, 2021_For posting.pdf sr0657-kesimpta-clinical-review-report.pdf sr0657-kesimpta-pharmacoeconomic-review-report.pdf SR0657 ofatumumab - Patient Input Group - For posting.pdf	Multiple Sclerosis, relapsing	Reimburse with clinical criteria and/or conditions	Complete	Aug 25, 2020	Feb 25, 2021	SR0657-000
Adult B-Cell Precursor Acute L...			Final Report	B-Cell Precursor Acute Lymphoblastic Leukemia		Complete		Feb 24, 2021	PH0002-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 351 - 375 of 602

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Heart Function Clinics for Patients with Heart Failure	Heart Function Clinics for Patients with Heart Failure	Sep 17, 2021	Rapid Review	Completed	RC1379-000
Occupational Screening for Latent Tuberculosis Infection	Occupational Screening for Latent Tuberculosis Infection	Sep 2, 2021	Rapid Review	Completed	RC1348-000
Hip Protectors for Community-Dwelling Older Adults	Hip Protectors for Community-Dwelling Older Adults	Sep 2, 2021	Rapid Review	Completed	RC1378-000
Anesthesia Care Provided by Nurses	Anesthesia Care Provided by Nurses	Sep 2, 2021	Rapid Review		RC1376-000
Shortened Drug Regimens for the Treatment of Active Tuberculosis	Shortened Drug Regimens for the Treatment of Active Tuberculosis	Aug 30, 2021	Summary with Critical Appraisal	Completed	RC1342-000
Prevention of Tuberculosis Reactivation	Prevention of Tuberculosis Reactivation	Aug 27, 2021	Rapid Review	Completed	RC1344-000
Medications Containing Low-dose Codeine for the Treatment of Pain and Coughs	Medications Containing Low-dose Codeine for the Treatment of Pain and Coughs	Aug 20, 2021	Rapid Review	Completed	RC1374-000
The Use of Cone Beam CT in Dental, Oral, and Maxillofacial Surgery, and Otolaryngology Settings	The Use of Cone Beam CT in Dental, Oral, and Maxillofacial Surgery, and Otolary…	Aug 11, 2021	Environmental Scan	Completed	ES0348-000
Chlorhexidine Gluconate for Skin Preparation During Catheter Insertion and Surgical Procedures	Chlorhexidine Gluconate for Skin Preparation During Catheter Insertion and Surg…	Aug 10, 2021	Rapid Review		RC1375-000
Community Pharmacist–Led Medication Reviews	Community PharmacistñLed Medication Reviews	Aug 9, 2021	Policy Insight	Completed	CY0005-000
Sustainability of Chronic Kidney Disease Care	Sustainability of Chronic Kidney Disease Care	Aug 6, 2021	Policy Insight	Completed	CY0011-000
Antipsychotic Drugs or Benzodiazepines for Rapid Tranquilization in Mental Health Facilities or Emergency Department Settings	Antipsychotic Drugs or Benzodiazepines for Rapid Tranquilization in Mental Heal…	Aug 5, 2021	Rapid Review	Completed	RC1373-000
Autologous Hematopoietic Cell Transplant for Patients With Multiple Sclerosis	Summary With Critical Appraisal - Rapid Response Report	Aug 5, 2021	Rapid Review		RC1356-000
Harm Reduction Interventions to Prevent Overdose	Harm Reduction Interventions to Prevent Overdose	Aug 5, 2021	Policy Insight	Completed	CY0008-000
Vitamin D Supplementation for the Prevention of Falls and Fractures in Residents of Long-Term Care Facilities: A 2021 Update	RC1371 VitD in LTC Fall Prevention Update Final.pdf	Jul 29, 2021	Rapid Review	Completed	RC1371-000
Point-of-Care Testing and N-Acetylcysteine for Acute Acetaminophen Overdose	Point-of-Care Testing and N-Acetylcysteine for Acute Acetaminophen Overdose	Jul 28, 2021	Rapid Review	Completed	RC1372-000
Vitamin D Supplementation for the Prevention and/or Treatment of Cardiovascular Disease, Cancer, and Other Conditions in Residents of Long-Term Care Facilities	Vitamin D Supplementation for the Prevention and/or Treatment of Cardiovascular…	Jul 28, 2021	Rapid Review	Completed	RC1370-000
Convalescent Plasma Therapy for the Treatment of COVID-19: A Review of Clinical Effectiveness	RC1288-007 Convalescent Plasma COVID_Final.pdf	Jul 26, 2021	Rapid Review	Completed	RC1288-007
Transcatheter Aortic Valve Implantation for Patients with Severe Symptomatic Aortic Stenosis	Transcatheter Aortic Valve Implantation for Patients with Severe Symptomatic Ao…	Jul 21, 2021	Summary with Critical Appraisal		RC1367-000
Palonosetron for Patients Undergoing High or Moderate Emetogenic Chemotherapy	Palonosetron for Patients Undergoing High or Moderate Emetogenic Chemotherapy	Jul 21, 2021	Summary with Critical Appraisal	Completed	RC1366-000
Implementation of Stereotactic Ablative Radiotherapy for the Treatment of Oligometastatic Cancer in Canada	Implementation of Stereotactic Ablative Radiotherapy for the Treatment of Oligo…	Jul 14, 2021	Environmental Scan	Completed	ES0352-000
Long-Term Care Personal Support Workers’ Resilience and Wellness	Long-Term Care Personal Support Workers’ Resilience and Wellness	Jul 9, 2021		Completed
Strategies Used by Long-Term Care Facilities to Maintain Communication With Essential Care Partners During a Pandemic or Infectious Disease Outbreak	Strategies Used by Long-Term Care Facilities to Maintain Communication With Ess…	Jul 8, 2021		Completed
Genetic Carrier Screening for Cystic Fibrosis, Fragile X Syndrome, Hemoglobinopathies, and Spinal Muscular Atrophy	RC1361_Genetic Carrier Screening Final.pdf	Jun 25, 2021	Rapid Review		RC1361-000
Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders	RC1363 Psychedelics Final.pdf	Jun 25, 2021	Rapid Review	Completed	RC1363-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 351 - 375 of 2138

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Evidence Review of Treatment Options for Uncomplicated Gonococcal Infections		Final Report Summary Report	Aug 6, 2024	Health Technology Review	Technology Review	Completed	RE0046-000
Re-Treatment With Immune Checkpoint Inhibitors		Final Report	Aug 6, 2024	Health Technology Review	Summary with Critical Appraisal	Completed	RC1544-000
Strategies to Reduce Alternate Level of Care	We analyzed CIHI data related to ALC and average length of ALC in older adults. We also conducted an environmental scan of the academic and grey literature to identify strategies to address ALC in older adults in Canada and strategies that have been effective in reducing ALC in older adults.	Final Report	Aug 6, 2024	Horizon Scan		Completed	EH0126-000
Large B cell lymphoma		Final Report	Aug 1, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0048-000
Cutaneous Melanoma		Final Report	Aug 1, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0049-000
Multiple Myeloma		Final Report	Aug 1, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0047-000
Drug Shortages in Canada		Final Report	Jul 31, 2024	Health Technology Review	Environmental Scan	Completed	ES0381-000
drospirenone		Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation	Jul 26, 2024	Reimbursement Review		Complete	SR0806-000
Pharmaceutical Reviews Update — Issue 49			Jul 25, 2024	Reimbursement Review	Pharmaceutical Review Update
solriamfetol			Jul 24, 2024	Reimbursement Review		Not filed	NS0039-000
solriamfetol			Jul 24, 2024	Reimbursement Review		Not filed	NS0038-000
zanubrutinib			Jul 24, 2024	Reimbursement Review		Not filed	NS0037-000
pembrolizumab			Jul 24, 2024	Reimbursement Review		Not filed	NS0034-000
trastuzumab deruxtecan			Jul 24, 2024	Reimbursement Review		Not filed	NS0035-000
capmatinib			Jul 24, 2024	Reimbursement Review		Not filed	NS0036-000
daratumumab			Jul 24, 2024	Reimbursement Review		Not filed	NS0031-000
liraglutide			Jul 24, 2024	Reimbursement Review		Not filed	NS0032-000
dexamethasone intravitreal implant			Jul 24, 2024	Reimbursement Review		Not filed	NS0033-000
dabrafenib and trametinib			Jul 24, 2024	Reimbursement Review		Not filed	NS0029-000
treosulfan			Jul 24, 2024	Reimbursement Review		Not filed	NS0030-000
omalizumab			Jul 24, 2024	Reimbursement Review		Not filed	NS0026-000
mepolizumab			Jul 24, 2024	Reimbursement Review		Not filed	NS0027-000
dabrafenib and trametinib			Jul 24, 2024	Reimbursement Review		Not filed	NS0028-000
sofosbuvir / velpatasvir			Jul 24, 2024	Reimbursement Review		Not filed	NS0024-000
fluticasone furoate/umeclidinium bromide/vilanterol trifenatate			Jul 24, 2024	Reimbursement Review		Not filed	NS0025-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81